21/07/2025
🚨 NEW STUDY ALERT! 🚨
Recent data from the international ( ) study sheds critical light on the diagnostic performance of axillary ultrasound (AUS) after neoadjuvant chemotherapy (NACT) in initially node-positive breast cancer.
The article is now published in the European Journal of Cancer Elsevier.
📌 Key findings from 3,260 patients:
✅ AUS showed a specificity of 78.9%
⚠️ Sensitivity was only 46.4% - 35.7% of patients with negative AUS still had nodal disease
🧬 Diagnostic accuracy varied significantly by tumor subtype, grade, and breast response
📣 Bottom line: US alone is not reliable enough to determine surgical strategy after NACT. Axillary surgery remains essential for accurate staging in cN+ patients. HOWEVER, our findings suggest that AUS continues to play a role in guiding surgical staging in this context, provided its results are interpreted considering the tumor subtype, grade, and breast tumor response.
🔗 Read the full publication: https://doi.org/10.1016/j.ejca.2025.115607
🙏 Huge thanks to the entire study team, 288 study sites across 26 countries, and all our collaborators and sponsors.
This work was supported by AGO-B, the Claudia von Schilling Foundation, Ehmann Foundation Savognin, AWOgyn, Endomag, A Hologic Company, Merit Medical Systems, and Mammotome.
This milestone in axillary management would not be possible without your commitment!
